{"generic":"Scorpion (Centruroides) Immune F(ab)2","drugs":["Anascorp","Scorpion (Centruroides) Immune F(ab)2"],"mono":{"0":{"id":"930000-s-0","title":"Generic Names","mono":"Scorpion (Centruroides) Immune F(ab)2"},"1":{"id":"930000-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930000-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Poisoning due to scorpion venom:<\/b> initial dose, 3 vials by IV infusion over 10 minutes as soon as possible after scorpion sting in patients who display clinically important signs of scorpion envenomation<\/li><li><b>Poisoning due to scorpion venom:<\/b> additional doses, administer 1 vial at a time by IV infusion over 10 minutes as needed at intervals of 30 to 60 minutes<\/li><\/ul>"},"1":{"id":"930000-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Poisoning due to scorpion venom:<\/b> initial dose, 3 vials by IV infusion over 10 minutes as soon as possible after scorpion sting in patients who display clinically important signs of scorpion envenomation<\/li><li><b>Poisoning due to scorpion venom:<\/b> additional doses, administer 1 vial at a time by IV infusion over 10 minutes as needed at intervals of 30 to 60 minutes<\/li><\/ul>"},"3":{"id":"930000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Poisoning due to scorpion venom<br\/>"}}},"3":{"id":"930000-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930000-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930000-s-3-10","title":"Precautions","mono":"<ul><li>severe hypersensitivity reactions, including anaphylaxis, may occur; monitoring recommended; discontinue therapy immediately if anaphylaxis occurs<\/li><li>antivenom made from equine plasma; may contain infectious agents (eg, viruses)<\/li><li>cresol contained as an excipient; localized reactions and generalized myalgias have been reported<\/li><li>delayed allergic reactions (serum sickness) may occur; monitoring recommended<\/li><li>equine (horse) protein allergy; increased risk for anaphylaxis<\/li><li>prior therapy with equine antivenom or antitoxin; increased risk for severe hypersensitivity<\/li><\/ul>"},{"id":"930000-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930000-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (2%), Rash (2.7%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (2.1%), Vomiting (4.7%)<\/li><li><b>Other:<\/b>Fever (4.1%)<\/li><\/ul>"},"6":{"id":"930000-s-6","title":"Drug Name Info","sub":{"0":{"id":"930000-s-6-17","title":"US Trade Names","mono":"Anascorp<br\/>"},"2":{"id":"930000-s-6-19","title":"Class","mono":"Antivenom<br\/>"},"3":{"id":"930000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930000-s-7","title":"Mechanism Of Action","mono":"Centruroides (scorpion) immune F(ab')2 (equine) injection is a polyvalent preparation of equine immune globulin F(ab')2 fragments, manufactured from plasma of horses immunized with venom of C. noxius, C.l. limpidus, C.l. tecomanus, and C.s.suffusus. Indicated for treatment of scorpion envenomation, it is composed of venom-specific F(ab')2 fragments of immunoglobulin G (IgG) that bind and neutralize venom toxins, facilitating redistribution away from target tissues and elimination from the body.<br\/>"},"8":{"id":"930000-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930000-s-8-24","title":"Distribution","mono":"Vd: 13.6 L <br\/>"},"3":{"id":"930000-s-8-26","title":"Excretion","mono":"Total body clearance: 83.5 mL\/hr <br\/>"},"4":{"id":"930000-s-8-27","title":"Elimination Half Life","mono":"159 hours <br\/>"}}},"9":{"id":"930000-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute each vial with 5 mL of NS and swirl gently<\/li><li>further dilute the initial dose (3 vials) or additional doses (1 vial) to a total volume of 50 mL with NS and infuse IV over 10 minutes<\/li><li>discard partially used vials<\/li><\/ul>"},"10":{"id":"930000-s-10","title":"Monitoring","mono":"<ul><li>resolution of signs and symptoms of envenomation (ie, loss of muscle control, roving or abnormal eye movements, slurred speech, respiratory distress, excessive salivation, frothing at the mouth, and vomiting) indicates efficacy<\/li><li>severe hypersensitivity reactions, including anaphylaxis, during the infusion<\/li><li>serum sickness or other delayed hypersensitivity reactions at follow-up visits<\/li><\/ul>"},"13":{"id":"930000-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause vomiting, nausea, diarrhea, cough, headache, or fatigue.<\/li><li>Instruct patient to immediately report signs\/symptoms of allergic reaction or serum sickness up to 14 days after treatment, including rash, itchy skin, joint pain or arthralgia, fever, lymphadenopathy, or malaise.<\/li><\/ul>"}}}